UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enhanced antibody half-life improves in vivo activity

Nature biotechnology, 2010-02, Vol.28 (2), p.157-159

2010

Volltextzugriff (PDF)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2914-2925

2021

Volltextzugriff (PDF)

Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases

Allergy (Copenhagen), 2024-09, Vol.79 (9), p.2565-2566

2024

Volltextzugriff (PDF)

Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents

Cellular and molecular neurobiology, 2021-07, Vol.41 (5), p.949-960

2021

Volltextzugriff (PDF)

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e002024

2021

Volltextzugriff (PDF)

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus

Journal of translational autoimmunity (Online), 2022-01, Vol.5, p.100152, Article 100152

2022

Volltextzugriff (PDF)

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

Journal for immunotherapy of cancer, 2022-04, Vol.10 (4), p.e004419

2022

Volltextzugriff (PDF)

NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases

Journal of translational autoimmunity (Online), 2021-01, Vol.4, p.100103-100103, Article 100103

2021

Volltextzugriff (PDF)

Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection

Journal of Immunology, 2007-08, Vol.179 (3), p.1872-1883

2007

Volltextzugriff (PDF)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003480

2021

Volltextzugriff (PDF)

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development

Frontiers in pain research (Lausanne, Switzerland), 2021-08, Vol.2, p.695962-695962

2021

Volltextzugriff (PDF)

Engineering IL-2 to Give New Life to T Cell Immunotherapy

Annual review of medicine, 2021-01, Vol.72 (1), p.281-311

2021

Volltextzugriff (PDF)

368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A224-A225

2020

Volltextzugriff (PDF)

420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A256-A256

2020

Volltextzugriff (PDF)

Transgene-mediated cosuppression in the C. elegans germ line

Genes & development, 2000-07, Vol.14 (13), p.1578-1583

2000

Volltextzugriff (PDF)

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Cancer discovery, 2019-06, Vol.9 (6), p.711-721

2019

Volltextzugriff (PDF)

Abstract 123: Enhanced anti-tumor activity of the combination of entinostat and NKTR214 in renal and colon cancer tumor models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.123-123

2018

Volltextzugriff (PDF)

NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells

The Journal of clinical investigation, 2021-10, Vol.131 (19), p.1-14

2021

Volltextzugriff (PDF)

CD38+ cell depletion with TAK-079 reduces arthritis in a cynomolgus collagen-induced arthritis (CIA) model

The Journal of immunology (1950), 2017-05, Vol.198 (1_Supplement), p.127-127.17

2017

Volltextzugriff (PDF)

A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys

The Journal of pharmacology and experimental therapeutics, 2019-08, Vol.370 (2), p.182-196

2019

Volltextzugriff (PDF)

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.7488-7490

2022

Volltextzugriff (PDF)

724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata

British journal of dermatology (1951), 2024-08, Vol.191 (Supplement_2)

2024

Volltextzugriff (PDF)

TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2567-2567

2018

Volltextzugriff (PDF)

Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3085-3085

2018

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology - Other Topics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(80)

Publikationsform

Sprache

Englisch
(94)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Enhanced antibody half-life improves in vivo activity

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases

Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases

Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development

Engineering IL-2 to Give New Life to T Cell Immunotherapy

368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

Transgene-mediated cosuppression in the C. elegans germ line

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Abstract 123: Enhanced anti-tumor activity of the combination of entinostat and NKTR214 in renal and colon cancer tumor models

NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells

CD38+ cell depletion with TAK-079 reduces arthritis in a cynomolgus collagen-induced arthritis (CIA) model

A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata

TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models

Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors

Aktive Filter

Suchergebnisse filtern